What happened: The U.S. Food and Drug Administration granted full approval to a new Alzheimer's treatment on July 6, less than three months after President Joe Biden formally announced his candidacy for reelection.
• Leqembi is the first new Alzheimer's treatment fully approved by the FDA in 20 years, and the first drug that slows progression of the cognitive disease.
• The FDA granted "accelerated approval" for Leqembi in January 2023, roughly three months after Biden attempted to converse with a dead congresswoman at a White House nutrition conference.
• The FDA is a federal agency housed within the Department of Health and Human Services, which is run by a presidential appointee. The timing of the drug's approval raises some troubling questions about government collusion and election interference.
Why it matters: This is great news for Biden's reelection campaign. Leqembi has been shown to "modestly slow the pace of cognitive decline" in Alzheimer's patients, according to the New York Times.
• A modest reduction may well suffice. Biden, 80, just needs to remain minimally upright and competent until Election Day on Nov. 5, 2024.
• In phase 3 clinical trials, patients taking Leqembi experienced a 27 percent slower rate of decline compared with the placebo group.
• Side effects include brain swelling, seizures, and death.
Crucial context: Biden reportedly has been prone to violent temper tantrums since taking office, which is a common symptom of Alzheimer's and other forms of cognitive decline.
• Biden's cognitive decline was likely exacerbated by his failure to properly treat his longstanding sleep apnea, the Washington Free Beacon reported in June.
Bottom line: Biden should be resting comfortably at home, surrounded by friends and family. Not running for reelection.